Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• V-domain Ig suppressor of T-cell activation (VISTA) is a negative regulator of antitumor immunity.
• VISTA is expressed in hematopoietic stem cells and myeloid cells and is upregulated in acute myeloid leukemia (AML).
• VISTA's role in myeloid malignancies is not well understood.

Purpose of the Study:

• To investigate the role of VISTA in immune escape in AML patients.
• To analyze VISTA mRNA expression and its correlation with leukemia burden and clinical outcomes in AML.

Main Methods:

• Bulk and single-cell RNA sequencing of leukemia cell lines and bone marrow samples from healthy individuals and AML patients.
• Whole-exome sequencing to assess correlations with leukemia-associated burden.
• Analysis of VISTA expression in relation to AML differentiation, mutations (NPM1, FLT3), and disease recurrence.

Main Results:

• VISTA expression increases with myeloid differentiation in normal hematopoiesis.
• VISTA is enriched in AML cell lines and diagnosed AML patients with myelomonocytic/monocytic differentiation.
• VISTA expression correlates with NPM1 mutations and predicts disease recurrence in normal karyotype AML patients, with higher levels in relapsing cases.

Conclusions:

• VISTA plays a role in immune escape in AML.
• VISTA expression is a potential biomarker for disease recurrence in specific AML subgroups.
• Targeting VISTA presents a rationale for novel therapeutic strategies in AML to overcome treatment resistance and prevent recurrence.